XOMA Royalty (LTS:0M26) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M26 XOMA Royalty Corp LTS:0M26
37 GF Score
Price $40.89
GF Value $18.97
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is XOMA Royalty FFO per Share?

FFO per Share only applies to REITs.

LTS:0M26
37GF Score
XOMA Royalty Corp LTS:0M26
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is XOMA Royalty (LTS:0M26) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $40.89 is trading 115.6% above its estimated GF Value™ of $18.97. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for LTS:0M26:

  • FFO per Share:
  • GF Value™: $18.97 vs. price of $40.89 (115.6% above fair value)
  • GF Score™: 37/100 with 8 warning signs

No single metric tells the full story. See the LTS:0M26 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
37GF Score

Get the complete analysis for LTS:0M26

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.89
Price
$18.97
GF Value